6505--Carbidopa Levodopa Immediate Release (IR) Tablets 36E79726R0008

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79726R0008 for an unrestricted procurement for Carbidopa Levodopa Immediate Release (IR)Tablets, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Solicitation # 36E79726R0008 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about December 18, 2025 with a tentative closing date of January 8, 2026. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Ray Roldan. Questions can be emailed to Raymond.Roldan@va.gov. The estimated annual requirements are as follows: Item Description Package Size (Tablets per Bottle) Total Estimated Annual Usage (Bottles) 1 Carbidopa 10MG/Levodopa 100MG IR Tablets 100 5,871 2a Carbidopa 10MG/Levodopa 100MG IR Tablets 500 4,016 OR OR OR OR 2b Carbidopa 10MG/Levodopa 100MG IR Tablets 1,000 2,008 3 Carbidopa 25MG/Levodopa 100MG IR Tablets 100 97,411 4a Carbidopa 25MG/Levodopa 100MG IR Tablets 500 118,764 OR OR OR OR 4b Carbidopa 25MG/Levodopa 100MG IR Tablets 1,000 59,382 5 Carbidopa 25MG/Levodopa 250MG IR Tablets 100 10,141 6a Carbidopa 25MG/Levodopa 250MG IR Tablets 500 7,614 OR OR OR OR 6b Carbidopa 25MG/Levodopa 250MG IR Tablets 1,000 3,807

N/A

Extend the due date and time for receipt of offers. See Amendment document for details.